Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to DO2003000728ApriorityCriticalpatent/DOP2003000728A/en
Publication of DOP2003000728ApublicationCriticalpatent/DOP2003000728A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Abstract
SE TRATA DE COMPUESTOS DE TIAZOL QUE INHIBEN LA PRODUCCION DE ALFABETA-PEPTIDOS. PROPORCIONA ADEMAS COMPOSICIONES FARMACEUTICAS Y METODOS QUE USAN ESTOS COMPUESTOS PARA TRATAR ENFERMEDADES COMO LA DE ALZHEIMERIT IS TIAZOL COMPOUNDS THAT INHIBIT ALPHABET-PEPTIDES PRODUCTION. ALSO PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS THAT USE THESE COMPOUNDS TO TREAT DISEASES LIKE ALZHEIMER'S
DO2003000728A2003-10-062003-10-06
TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENETIVE DISORDERS
DOP2003000728A
(en)
Polymorphic form, pharmaceutical composition, methods for treating an inflammatory disease, a cyclooxygenase-mediated disease, pain, and a process for making a polymorph v